Metropolis Healthcare Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the Bombay Stock Exchange and National Stock Exchange on July 27, 2026. The filing, mandated under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines the company’s progress on environmental stewardship, social responsibility, and governance frameworks. For FY26, the company reported a turnover of ₹1,36,547.17 lakh and a net worth of ₹1,38,910.53 lakh, reinforcing its scale as it pursues long-term sustainability goals including net-zero emissions by FY2043.

The report details significant strides in renewable energy adoption, with approximately 30% of electricity at the Metropolis Global Reference Laboratory sourced from renewables. The company has initiated a 100kW rooftop solar programme across select facilities and aims to source ~50% of its electricity from renewable sources by FY2030. Additionally, Metropolis targets a 45% reduction in greenhouse gas emissions intensity by FY2030 and a 30% reduction in water intensity by FY2043. These environmental commitments are supported by infrastructure upgrades, including LED lighting retrofits and HVAC optimization.

Workforce Diversity and Social Impact

On the social front, Metropolis reported that women constitute approximately 44% of its overall workforce, progressing toward its goal of a 50:50 gender-balanced workforce by FY2028. The company maintains a Net Promoter Score (NPS) of 87, reflecting customer satisfaction. Its Corporate Social Responsibility (CSR) initiatives reached over 13 lakh beneficiaries through the Adolescent Reproductive and Sexual Health (ARSH) programme and preventive healthcare campaigns. In FY26, the company spent ₹56,08,255 on CSR projects in designated aspirational districts across multiple states.

Operational Footprint and Governance

Metropolis operates 212 laboratories nationally and five offices internationally, serving markets in Kenya, Zambia, Ghana, Tanzania, and Uganda, alongside B2B clients in 16 other countries. Exports contributed 3.31% to total turnover. The company maintains ISO 27001 and ISO 27701 certifications for information security and privacy, with no data breaches reported during the year. The CSR & ESG Committee, chaired by Chairperson & Whole-time Director Ameera Shah, oversees these sustainability efforts.

Key Financial and Operational Metrics

What the Numbers Show

The integration of sustainability into core operations is evident in Metropolis’s shift toward renewable energy and digital efficiency. With exports accounting for only 3.31% of turnover, the company’s primary growth and sustainability impact remain domestic, where it manages a dense network of 212 labs. The high NPS of 87 suggests that operational enhancements, such as the 'Go Digital, Go Green' initiative which reduces paper usage, are positively influencing customer experience without compromising service quality. The commitment to zero waste to landfill by FY2030 indicates a strategic focus on waste management, critical for a diagnostic service provider handling biomedical waste.

Metropolis Healthcare delivered a robust financial performance in Q1 FY27, reporting a 16% year-over-year revenue growth. The growth was underpinned by a rise in patient volumes and improved revenue realizations across its service offerings, signaling healthy demand for diagnostic services during the quarter.

Key Growth Drivers

The company's revenue expansion was supported by multiple factors working in tandem. Higher patient footfall contributed meaningfully to the top-line improvement, while better revenue realizations per patient further amplified the overall growth. These twin drivers reflect both an increase in the breadth of services consumed and an enhancement in the value of services rendered.

Segment Performance

The Truhealth Wellness and Specialty segments emerged as standout performers during Q1 FY27. Strong performance in these segments indicates growing consumer adoption of wellness-focused diagnostics as well as specialized testing services, both of which are higher-value offerings within Metropolis Healthcare's portfolio. B2C registered healthy volume growth, driven by increased throughput from the expanded center network, while B2B volumes grew supported by higher wallet share and new customer acquisition.

Margin Improvement

Alongside revenue growth, Metropolis Healthcare also reported improved EBITDA margins in Q1 FY27. The margin expansion suggests that the company managed its cost base effectively even as it scaled revenues, pointing to operational leverage playing a positive role during the quarter. On a quarter-on-quarter basis, margins remained largely stable.